.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,061,703

« Back to Dashboard

Claims for Patent: 5,061,703

Title: Adamantane derivatives in the prevention and treatment of cerebral ischemia
Abstract:A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
Inventor(s): Bormann; Joachim (Frankfurt, DE), Gold; Markus R. (Nauheim, DE), Schatton; Wolfgang (Eschborn, DE)
Assignee: Merz + Co. GmbH & Co. (Frankfurt am Main, DE)
Application Number:07/508,109
Patent Claims: 1. A method for the prevention or treatment of cerebral ischemia comprising the step of administering, to a patient in need thereof, an effective amount of an adamantane derivative of the general formula ##STR5## wherein R.sub.1 and R.sub.2 are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;

wherein

R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;

wherein

R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group,

or a pharmaceutically-acceptable salt thereof.

2. A method according to claim 1, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen.

3. A method according to claim 2, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen, and R.sub.3 and R.sub.4 are methyl.

4. A method according to claim 2, wherein R.sub.1, R.sub.2 and R.sub.5 are hydrogen, and R.sub.3 and R.sub.4 are ethyl.

5. A method according to claim 1, wherein R.sub.1, R.sub.2, R.sub.4 and R.sub.5 are hydrogen, and R.sub.3 is ethyl, isopropyl, or cyclohexyl.

6. A method according to claim 1, wherein R.sub.2 and R.sub.5 are hydrogen.

7. A method according to claim 6, wherein R.sub.3 and R.sub.4 are methyl, R.sub.2 and R.sub.5 are hydrogen and R.sub.1 is methyl or ethyl.

8. A method according to claim 1, wherein R.sub.1 and R.sub.2 are hydrogen.

9. A method according to claim 8, wherein R.sub.1 and R.sub.2 are hydrogen, R.sub.3 is ethyl, and R.sub.5 and R.sub.4 are methyl.

10. A method according to claim 1 for the treatment of Alzheimer's disease.

11. A method of claim 1, wherein the adamantane derivative is administered in an effective cerebral ischemia-alleviating or preventive amount.

12. A method of claim 11, wherein the adamantane derivative is administered in the form of a composition containing the same together with a pharmaceutically-acceptable carrier or diluent.

13. A method of claim 11, wherein the adamantane derivative is administered in an amount effective to prevent degeneration and loss of nerve cells after ischemia.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc